Pharmacokinetics of cyclosporine in recipients of marginal versus standard liver transplants

In the field of transplants, the practice of using marginal donor livers has become widely accepted, yielding good clinical results. This study investigated and compared the pharmacokinetics of cyclosporine in marginal and standard liver transplant recipients.Twenty-four de novo liver transplant patients, 12 with marginal and 12 with standard (normal) grafts, were treated with a microemulsion formulation of cyclosporine (capsules 100 mg) as immunosuppressive therapy. Blood concentration profiles were measured, and pharmacokinetic calculations performed at days 3 and 10 after transplantation. Different sampling strategies to predict drug exposure (AUC0–12 h) were compared, and the best limited-sampling strategies to monitor the desired blood levels were determined.Marginal and standard patients showed a significant difference in blood concentration and pharmacokinetic profiles of cyclosporine at the day 10 post-transplantation. Blood concentration at 4 h (C4 h) was the single best timepoint to estimate AUC0–12 h in marginal liver transplant (r2 = 0.700), while C2 h was confirmed to be the optimal choice with standard graft (r2 = 0.720). Two blood samples at 2 and 6 h significantly improved the prediction model in both groups (r2 = 0.920).Our data suggest that patients receiving a marginal liver transplant present a different pharmacokinetic profile of cyclosporine from those receiving standard graft, which should be taken into account in dosing the patient to avoid subtherapeutic blood concentrations or toxic effects.